Cagla KARAOGLU

Dr. Cagla KARAOGLU

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
HBHülya Odabaşı bükün
Hülya Odabaşı bükün
ECErdem Cubukcu
Erdem Cubukcu
ADAdem Deligonul
Adem Deligonul
AŞAhmet Bilgehan Bilgehan Şahin
Ahmet Bilgehan Bilgehan Şahin
ACAlper Coskun
Alper Coskun
TETürkkan Evrensel
Türkkan Evrensel
Background/Objectives: Phyllodes tumors (PTs) are rare fibroepithelial breast neoplasms with highly variable clinical behavior. Identifying predictive immunohistochemical markers is crucial for early detection of lesions with malignant potential and appropriate treatment selection. This study aimed to evaluate the association of insulin-like growth factor II mRNA-binding protein 3 (IMP3) and cluster of differentiation 10 (CD10) expression with histopathological grade and survival outcomes in PTs. Methods: We retrospectively analyzed sixty-eight female patients with PTs at Uludag University Faculty of Medicine Hospital, between 2000 and 2024. Histopathological features, IMP3 and CD10 expression, and clinical outcomes were evaluated. Disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method and compared using the log-rank test. Results: Among the 68 patients (median age: 39.0 years), 60.3% had benign PTs, 14.7% had borderline PTs, and 25.0% had malignant PTs. Histopathological parameters differed significantly across grades (all p < 0.01). IMP3 expression was strongly associated with higher histological grade, larger tumor size, and stromal atypia (p < 0.05). OS differed significantly by histological grade (p = 0.009) and IMP3 status (p = 0.013), whereas DFS and CD10 expression showed no significant associations (p > 0.05). Conclusions: IMP3 expression is strongly associated with malignant histology and poorer overall survival in PTs; however, its independent prognostic value could not be conclusively established due to the limited number of outcome events. While IMP3 may serve as a promising marker in routine pathological assessment, validation in larger, prospective cohorts with sufficient event numbers is warranted.

14 October 2026 in Archives of Rheumatology
Verified
Journal Article
Open access
PDF file
CKCagla KARAOGLU
Cagla KARAOGLU
ÖPÖzlem Pehlivan
Özlem Pehlivan
HGHalise Hande Gezer
Halise Hande Gezer
RSRıdvan Sivritepe
Rıdvan Sivritepe
FKFatma Kulali
Fatma Kulali
SBSema Basat
Sema Basat
Background/Aims: Sarcopenia has gained increasing attention as a potential comorbidity in axial spondyloarthritis (axSpA). This study aimed to assess the frequency of sarcopenia in patients with axSpA and to investigate its association with tumor necrosis factor inhibitor (TNFi) therapy. A secondary objective was to explore the potential value of ultrasound-based muscle measurements in identifying sarcopenia. Materials and Methods: This cross-sectional study enrolled 62 adult patients with axSpA who were evaluated during routine rheumatology follow-up. Clinical data, including disease activity, functional status, and spinal mobility, were recorded. Muscle strength, physical performance, and body composition were assessed in accordance with current sarcopenia definitions. Selected thigh and lumbar muscle parameters were measured using musculoskeletal ultrasound. Statistical analyses included comparative tests and regression modeling. Results: Probable sarcopenia was identified in 22.6% of patients, while 12.9% met the criteria for sarcopenia; no cases of severe sarcopenia were detected. Sarcopenia was observed less frequently among patients receiving TNFi therapy compared with those not treated with TNFi. TNFi use was associated with a reduced likelihood of sarcopenia. Ultrasound measurements of the rectus femoris muscle showed modest associations with sarcopenia status, although their diagnostic performance was limited. Conclusion: Sarcopenia is common in patients with axSpA. In this cross-sectional study, TNFi use was associated with a lower prevalence of sarcopenia, although a causal relationship cannot be established. Ultrasound-derived muscle parameters showed limited discriminatory performance and should be considered exploratory. Cite this article as: Karaoğlu Ç, Pehlivan Ö, Gezer HH, Sivritepe R, Kulalı F, Basat S. Sarcopenia in Patients with Axial Spondyloarthritis: Associations with TNF Inhibitor Therapy and Exploratory Ultrasound Findings. ArchRheumatol. Published online October 14, 2026. doi: 10.5152/ ArchRheumatol.2026.26292.

7 October 2026 in World Journal of Nuclear Medicine
Verified
Journal Article
Open access
Seçkin BilgiçSeçkin Bilgiç
Seçkin Bilgiç
CKCagla KARAOGLU
Cagla KARAOGLU
EÇElif İşleyen Çolak
Elif İşleyen Çolak
ECErdem Cubukcu
Erdem Cubukcu
EAEray Alper
Eray Alper
The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) in monitoring basal cell carcinoma (BCC) during vismodegib therapy remains poorly defined, particularly in patients with extensive, multifocal, or Gorlin syndrome–associated disease. This study aimed to evaluate metabolic and anatomic treatment-response findings and the incremental diagnostic value of 18F-FDG PET beyond CT in this setting. Patients with histopathologically confirmed BCC who underwent 18F-FDG PET/CT during vismodegib therapy between December 2015 and August 2026 were retrospectively reviewed. Metabolic response was classified using PERCIST (Positron Emission Tomography Response Criteria in Solid Tumors)-like criteria based on serial maximum standardized uptake value (SUVmax) measurements, and tumor-to-liver ratio (TLR) was additionally calculated as a background-normalized metabolic parameter. Patients without suitable paired imaging for metabolic response assessment because of absent follow-up PET/CT, lack of an FDG-avid target lesion, or intervening local treatment were considered not evaluable for categorical metabolic response. Baseline and follow-up SUVmax and TLR values were compared using the Wilcoxon signed-rank test. Continuous variables were summarized using descriptive statistics, and categorical variables were reported as frequencies and percentages. Sixteen patients were included, of whom 5 had Gorlin syndrome. Primary lesions were predominantly craniofacial, occurring in 15 of 16 patients (93.8%), and 11 patients had orbital involvement. Baseline FDG avidity was present in 10 patients, whereas 6 had low or absent uptake. Among 8 patients with paired quantitative PET/CT measurements, the median baseline and follow-up SUVmax values were 5.45 and 4.50, respectively, with no significant interval change (Wilcoxon signed-rank test, p = 1.000). Similarly, paired TLR values showed no significant interval change (p = 0.834). Categorical PET response assessment was feasible in seven patients. Others were not evaluable because of absent follow-up PET/CT, no FDG-avid target lesion, or intervening local treatment. A CT-measurable target lesion was present in nine patients (56.2%), while PET provided incremental information beyond the CT component in three patients (18.8%), primarily through the identification of additional metabolically active lesions or disease findings not apparent on CT. Although 18F-FDG PET/CT may provide additional metabolic information in selected patients with advanced, multifocal, or Gorlin syndrome–associated BCC, its incremental diagnostic contribution beyond CT during vismodegib therapy appears limited. Selective use may therefore be more appropriate than routine serial imaging.